AbbVievsKestra Medical Technologies

ABBV and KMTS stock compared: price, dividend, valuation and results, from SEC filings.

KMTS

Kestra Medical Technologies, Ltd.

$27.97

Value $1.6B

-2.34%
KMTS's page

AbbVie (ABBV) has a market value of $521B and Kestra Medical Technologies (KMTS) $1.6B. Over the last year, with dividends, ABBV moved +30.6% and KMTS +11.8%. Dividend yield: ABBV 2.35%, KMTS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$521B

    KMTS$1.6B

    ABBV is 318 times KMTS

  • Revenue, 12 months

    ABBV$66.0B

    KMTS$107M

    ABBV is 619 times KMTS

  • Net income, 12 months

    ABBV$10.3B

    KMTS-$150M

  • Operating margin

    ABBV32.2%

    KMTS-134.5%

    166.7 points apart

  • ROIC

    ABBV25.7%

    KMTS-41.7%

    67.4 points apart

  • P/E

    ABBV50.6

    KMTS–

  • Dividend yield

    ABBV2.4%

    KMTS0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+30.6%

KMTS+11.8%

80100120DecFebAprJunAugOct
Returns by period
PeriodABBVWith dividendsKMTSWith dividends
1 year since November 14, 2025+30.6%Price +26.8%+11.8%Price +11.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieKMTSKestra Medical Technologies

Valuation

ABBVKMTS
Valuation
Price$294.55$27.97
Market value$521B$1.6B
Enterprise value (EV)$591B–
P/E50.6–
P/E, 5-year median57.0–
P/B–7.4
EV/EBIT27.8–
Free cash flow yield3.6%–

Results and growth

ABBVKMTS
Results and growth
Revenue, 12 months$66.0B$107M
Net income, 12 months$10.3B-$150M
Free cash flow, 12 months$18.9B-$123M
Earnings per share, 12 months$5.81-$2.67
Revenue growth, year on year8.6%59.0%
Revenue growth a year, past+5.9%over 5 years+84.9%over 2 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVKMTS
Margins and returns on capital
Gross margin73.7%53.9%
Operating margin32.2%-134.5%
Net margin15.7%-140.4%
ROIC25.7%-41.7%
ROE–-67.0%

Balance sheet

ABBVKMTS
Balance sheet
Cash$10.8B$245M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×-19.0×

Dividends and buybacks

ABBVKMTS
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or KMTS

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Kestra Medical Technologies?

By market value, AbbVie ($521B) is about 317.7 times Kestra Medical Technologies ($1.6B), at today's prices.

How did ABBV and KMTS stock do over the last 1 years?

Since November 14, 2025, ABBV's price moved +26.8% and KMTS's +11.8%. With dividends: ABBV +30.6% (+30.6% a year), KMTS +11.8% (+11.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or KMTS?

The dividend yield at today's price is 2.35% for AbbVie and none for Kestra Medical Technologies. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Kestra Medical Technologies?

Over the last twelve months, the net margin was 15.7% for AbbVie and -140.4% for Kestra Medical Technologies, and the operating margin 32.2% and -134.5%. Revenue was $66.0B and $107M.

Which is the better investment, AbbVie or Kestra Medical Technologies?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.